UK GPs to test for asthma using Pharmaxis’ Aridol
Thursday, 12 August, 2004
Having recently completed the Phase III clinical trials for its patented asthma prognostic, Aridol, Sydney-based Pharmaxis (ASX: PXS) today announced that the first patients had been enrolled in a major UK clinical study.
This will be the first in-field use of Aridol by GPs, and will allow comparisons between Aridol and existing diagnosis techniques used for asthma and chronic obstructive pulmonary disease. Some 16 per cent of people now diagnosed with asthma do not have the disease. The study will follow patients for 12 months and is expected to complete in 2006.
Pharmaxis, meanwhile, is analysing its Phase III data, a process expected to be completed by September. A positive outcome would allow the company to apply to Australian and European pharmaceutical regulatory agencies later this year for permission to begin marketing the test in 2005.
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
